Amyloid beta A4 precursor protein-binding family A member 2 (APBA2)

Amyloid beta A4 precursor protein-binding family A member 2 (APBA2, also known as MINT2 or X11-beta) is a neuronal adaptor protein and member of the X11 protein family[1][2][3][4]. APBA2 possesses a central phosphotyrosine-binding (PTB) domain and two C-terminal PDZ domains[2][4], allowing it to interact with several synaptic proteins and with the amyloid precursor protein (APP). By binding to APP, APBA2 stabilizes this protein and inhibits its amyloidogenic cleavage, thus reducing the creation of the amyloid-β peptide implicated in Alzheimer’s disease pathogenesis[1][2][3][4]. APBA2 is also implicated in synaptic vesicle exocytosis, signal transduction, and neuronal cell adhesion, functioning as a scaffold protein that organizes protein complexes in the neuronal synapse[1][4]. Variations and reduced expression of APBA2 are associated with neurodegenerative and neuropsychiatric disorders, including Alzheimer’s disease, autism spectrum disorder, and schizophrenia, highlighting its essential role in both synaptic integrity and neural development[1][2][3][4].

Other names

MINT2X11LX11-betaMint-2D15S1518ELIN-10Adapter protein X11betaNeuronal Munc18-1-interacting protein 2HsT16821MGC:14091Neuron-specific X11L proteinphosphotyrosine-binding/-interacting domain (PTB)-bearing protein

Experimental APP modulators: Reduction in APBA2 function can decrease amyloid-β production by altering APP processing[1]. Not used as a direct molecular drug target in clinical practice as of current reports[1][3].